Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Analysis of Circulating Tumor Markers in Blood (ALCINA2)
NCT04025541Recruiting
- Sponsor
- Institut du Cancer de Montpellier
- Start
- May 2018
- Primary completion
- May 2026
- Countries
- 1
01
Overview
Open-label trial (13 cohorts), sponsored by Institut du Cancer de Montpellier. Primary endpoint: Estimation of the feasibility of the various blood tumoral biomarkers analysis at 4 years. Started May 2018; status: recruiting.
Beyond the preview
Go deeper on NCT04025541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04025541.